Navigation Links
Ranbaxy Gets FDA Approval for Hypertension Drug

Indian pharma major Ranbaxy Laboratories Limited has received the approval from the US Food and Drug //Administration (FDA) to manufacture and market generic hypertension drug Atenolol in the country.

Ranbaxy plans to market Atenolol tablets of 25 mg, 50 mg, and 100 mg dosage manufactured by Mumbai-based Ipca Laboratories in the US from the first quarter of 2007, the company said in a statement Tuesday.

Ipca Laboratories has an arrangement with Ranbaxy's wholly owned Florida-based subsidiary Ranbaxy Pharmaceuticals Inc (RPI) for marketing its products in the US.

"The Office of Generic Drugs of the US Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Tenormin of AstraZeneca LP," Ranbaxy said.

Atenolol is indicated in the management of hypertension. It may be used alone or concomitantly with other anti-hypertensive agents, particularly with a thiazide-type diuretic.

"We are pleased to receive this final FDA approval to market Atenolol tablets. This will further expand our product portfolio of affordable generic alternatives to the brand in the treatment of cardiovascular disorders," said Jim Meehan, vice president (sales and marketing) for Ranbaxy Pharmaceuticals Inc.

"This approval is the result of a strategic alliance with Ipca Laboratories that will develop a number of generic prescription pharmaceutical products which will be marketed by RPI in the US," he added.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... 18, 2017 , ... “Prompted By Love”: a love story thrown into doubt ... Nettles. Author Mary P. Nettles has devoted her life to ministry since the ... lifelong desire to write was, however, not fulfilled until 2014 when "The Color of ...
(Date:8/18/2017)... ... ... “Case #10-5411 Veterans Administration”: a personal account of corruption ... Administration” is the creation of published author, Carol Mulhern, single mother of two ... work at the Coatesville VAMC as a file clerk then later became the ...
(Date:8/17/2017)... ... August 17, 2017 , ... Shared leadership between ... extremely effective, very effective, or effective by 85% of respondents, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait left the ... took with her a dream to make nursing education more relevant and prepare aspiring ... skills were integrated into healthcare provider education. , “The human element was ...
(Date:8/17/2017)... ... August 17, 2017 , ... CARF ... three years for its residential drug and alcohol detox program. This accreditation decision ... and shows the organization’s substantial conformance to the CARF standards. , Behavioral health ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  AOTI Inc. announced today that its fully owned ... a New York City Office in Yonkers, New York ... Wound Oxygen (TWO 2 ) homecare therapy. This new East Coast ... Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment ... Advanced Oxygen Therapy ...
(Date:8/8/2017)... --   Second-quarter 2017 revenues ... per share from continuing operations ... percent to $110 million ... $161 million Second-quarter 2017 ... increased 8 percent to $0.93 ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
Breaking Medicine Technology: